Trial · NCT03292653
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Placebo | AEs | 40 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 200 mg | AEs | 30 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 400 mg | AEs | 45.5 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Placebo | SAEs | 10 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 200 mg | SAEs | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 400 mg | SAEs | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Placebo | AESIs | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 200 mg | AESIs | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 400 mg | AESIs | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Placebo | AEs Leading to Discontinuation From the IMP | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 200 mg | AEs Leading to Discontinuation From the IMP | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 400 mg | AEs Leading to Discontinuation From the IMP | 9.1 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Placebo | Deaths | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 200 mg | Deaths | 0 | percentage of participants | |
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths | Sotagliflozin 400 mg | Deaths | 0 | percentage of participants | |
| Change From Baseline in Hemoconcentration as Assessed by Changes in Albumin to Day 14 | Placebo | 1.17 | Standard Error 2.71 | g/L | |
| Change From Baseline in Hemoconcentration as Assessed by Changes in Albumin to Day 14 | Sotagliflozin 200 mg | 2.44 | Standard Error 2.40 | g/L | |
| Change From Baseline in Hemoconcentration as Assessed by Changes in Albumin to Day 14 | Sotagliflozin 400 mg | 0.15 | Standard Error 2.14 | g/L | |
| Change From Baseline in Hemoconcentration as Assessed by Changes in Hematocrit to Day 14 | Placebo | 0.02 | Standard Error 0.02 | percentage of red blood cells | |
| Change From Baseline in Hemoconcentration as Assessed by Changes in Hematocrit to Day 14 | Sotagliflozin 200 mg | -0.02 | Standard Error 0.02 | percentage of red blood cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292653/results